Pulse Biosciences/$PLSE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pulse Biosciences
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Ticker
$PLSE
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
75
ISIN
US74587B1017
Website
PLSE Metrics
BasicAdvanced
$1.1B
-
-$0.99
1.60
-
Price and volume
Market cap
$1.1B
Beta
1.6
52-week high
$25.00
52-week low
$13.50
Average daily volume
188K
Financial strength
Current ratio
15.581
Quick ratio
15.371
Long term debt to equity
6.054
Total debt to equity
7.241
Profitability
EBITDA (TTM)
-62.524
Management effectiveness
Return on assets (TTM)
-43.61%
Return on equity (TTM)
-77.86%
Valuation
Price to book
9.13
Price to tangible book (TTM)
9.43
Price to free cash flow (TTM)
-24.315
Free cash flow yield (TTM)
-4.11%
Free cash flow per share (TTM)
-66.09%
Growth
Earnings per share change (TTM)
27.11%
3-year earnings per share growth (CAGR)
-22.88%
What the Analysts think about PLSE
Analyst ratings (Buy, Hold, Sell) for Pulse Biosciences stock.
Bulls say / Bears say
Pulse Biosciences has received U.S. FDA Breakthrough Device Designation and Total Product Life Cycle (TPLC) Advisory Program (TAP) designation for its Cardiac Surgery System, indicating strong regulatory support for its innovative technology. (finance.yahoo.com)
The company successfully completed initial procedures in its first-in-human feasibility study for atrial fibrillation treatment in Europe, demonstrating progress in clinical applications. (finance.yahoo.com)
Pulse Biosciences strengthened its balance sheet by raising $47.9 million through warrant exercises in Q4 2024, enhancing its financial position for future developments. (investing.com)
The company reported a GAAP net loss of $19.4 million in Q4 2024, an increase from $11.9 million in the prior year, indicating escalating operational expenses. (gurufocus.com)
Total GAAP costs and expenses rose to $20.3 million in Q4 2024, up from $12.5 million in the same period last year, primarily due to higher stock-based compensation and administrative expenses. (investing.com)
Analysts have expressed skepticism about the commercial viability of Pulse Biosciences' Nano-Pulse Stimulation technology, citing previous setbacks and questioning its potential success in new applications. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
PLSE Financial Performance
Revenues and expenses
PLSE Earnings Performance
Company profitability
PLSE News
AllArticlesVideos
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 months ago
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pulse Biosciences stock?
Pulse Biosciences (PLSE) has a market cap of $1.1B as of July 15, 2025.
What is the P/E ratio for Pulse Biosciences stock?
The price to earnings (P/E) ratio for Pulse Biosciences (PLSE) stock is 0 as of July 15, 2025.
Does Pulse Biosciences stock pay dividends?
No, Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Pulse Biosciences dividend payment date?
Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders.
What is the beta indicator for Pulse Biosciences?
Pulse Biosciences (PLSE) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.